Our Work in Neurology

The multiple sclerosis (MS) market is more dynamic than ever with more than 14 disease-modifying therapies (DMTs) currently available. In addition, evolving attitudes around safety issues balanced with earlier treatment with aggressive therapy has made the competitive environment increasingly complex. With the launch of the first anti-CGRP agent, the migraine market gains a new class which will shift current competitive patterns.

Diseases Covered

Multiple Sclerosis, Migraine, Rare Neurological Diseases

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.

RECENT PUBLICATIONS

Spherix Global Insights’ Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme’s Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis – December 11, 2018
>VIEW ARTICLE

Recent Progressive Forms of Multiple Sclerosis Chart Audit Provides Evidence That the Institute for Clinical and Economic Review’s Comparators of Interest for Novartis’ Siponimod Assessment May Not Be Relevant for the Not Active Secondary Progressive Multiple Sclerosis Segment – November 13, 2018
>VIEW ARTICLE

Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone – October 9, 2018
>VIEW ARTICLE

UPCOMING CONFERENCES

ECTRIMS 2018
>LEARN MORE

HELPFUL LINKS

MSAA Logo
National MS Society Logo